Additional value of 68GA-PSMA PET in patients who underwent choline-pet for biochemical recurrence after radical treatment for prostate cancer

Schwenck J et al. Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. J Nucl Med 2019; 60: 1359–1365 15–40 % der Patienten mit einem Prostatakarzinom erleiden postoperativ ein biochemisches Rezidiv. In der retrospektiven Analyse beeinflussten die Bildgebungsverfahren die Häufigkeit einer richtigen Therapiewahl. Die Autoren empfehlen die 68Ga-PSMA-PET/CT, die die höchste Genauigkeit aufwies. Unter Berücksichtigung der Kosten für inadäquate Behandlungen entstünden keine ökonomischen Nachteile.

Download Full-text

Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques

Radiation Oncology ◽

10.1186/s13014-020-01733-x ◽

2021 ◽

Vol 16 (1) ◽

Author(s):

Lindsay S. Rowe ◽

Stephanie Harmon ◽

Adam Horn ◽

Uma Shankavaram ◽

Soumyajit Roy ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Pet Imaging ◽

Biochemical Recurrence ◽

Imaging Techniques ◽

Specific Antigen ◽

Definitive Treatment ◽

Pattern Of Failure ◽

Link Type ◽

Psma Pet

Abstract Background Prostate Membrane Specific Antigen (PSMA) positron emission tomography (PET) and multiparametric MRI (mpMRI) have shown high accuracy in identifying recurrent lesions after definitive treatment in prostate cancer (PCa). In this study, we aimed to outline patterns of failure in a group of post-prostatectomy patients who received adjuvant or salvage radiation therapy (PORT) and subsequently experienced biochemical recurrence, using 18F-PSMA PET/CT and mpMRI. Methods PCa patients with biochemical failure post-prostatectomy, and no evident site of recurrence on conventional imaging, were enrolled on two prospective trials of first and second generation 18F-PSMA PET agents (18F-DCFBC and 18F-DCFPyL) in combination with MRI between October 2014 and December 2018. The primary aim of our study is to characterize these lesions with respect to their location relative to previous PORT field and received dose. Results A total of 34 participants underwent 18F-PSMA PET imaging for biochemical recurrence after radical prostatectomy and PORT, with 32/34 found to have 18F-PSMA avid lesions. On 18F-PSMA, 17/32 patients (53.1%) had metastatic disease, 8/32 (25.0%) patients had locoregional recurrences, and 7/32 (21.9%) had local failure in the prostate fossa. On further exploration, we noted 6/7 (86%) of prostate fossa recurrences were in-field and were encompassed by 100% isodose lines, receiving 64.8–72 Gy. One patient had marginal failure encompassed by the 49 Gy isodose. Conclusions 18F-PSMA PET imaging demonstrates promise in identifying occult PCa recurrence after PORT. Although distant recurrence was the predominant pattern of failure, in-field recurrence was noted in approximately 1/5th of patients. This should be considered in tailoring radiotherapy practice after prostatectomy. Trial registrationwww.clinicaltrials.gov, NCT02190279 and NCT03181867. Registered July 12, 2014, https://clinicaltrials.gov/ct2/show/NCT02190279 and June 8 2017, https://clinicaltrials.gov/ct2/show/NCT03181867.

Download Full-text

Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence

Nuclear Medicine Communications ◽

10.1097/mnm.0000000000001459 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Berna Okudan ◽

Nazim Coşkun ◽

Bedri Seven ◽

Merve Ağcioğlu Atalay ◽

Aslihan Yildirim ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Biochemical Recurrence ◽

Psma Pet ◽

Pet Ct

Download Full-text

The value of intravenous contrast medium in PSMA PET/CT imaging in patients with biochemical recurrence of prostate cancer

Nuclear Medicine Communications ◽

10.1097/mnm.0000000000001453 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Alain Winiger ◽

Maria del Sol Pérez Lago ◽

Dirk Lehnick ◽

Justus E. Roos ◽

Klaus Strobel

Keyword(s):

Prostate Cancer ◽

Contrast Medium ◽

Biochemical Recurrence ◽

Ct Imaging ◽

Intravenous Contrast ◽

Intravenous Contrast Medium ◽

Psma Pet ◽

Pet Ct

Download Full-text

PD32-08 CHOLINE PET/CT SCAN FOR THE DETECTION OF NODAL RELAPSES OF PROSTATE CANCER AFTER BIOCHEMICAL RECURRENCE: RESULTS FROM A MULTICENTRIC STUDY

The Journal of Urology ◽

10.1016/j.juro.2015.02.2119 ◽

2015 ◽

Vol 193 (4S) ◽

Author(s):

Marco Oderda ◽

Paolo Gontero ◽

Guglielmo Melloni ◽

Stefania Munegato ◽

Marco Falcone ◽

...

Keyword(s):

Prostate Cancer ◽

Ct Scan ◽

Biochemical Recurrence ◽

Multicentric Study ◽

Choline Pet ◽

Pet Ct ◽

Pet Ct Scan

Download Full-text

Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact

Cancers ◽

10.3390/cancers13194982 ◽

2021 ◽

Vol 13 (19) ◽

pp. 4982

Author(s):

Carlos Artigas ◽

Romain Diamand ◽

Qaid Ahmed Shagera ◽

Nicolas Plouznikoff ◽

Fabrice Fokoue ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Predictive Factors ◽

Clinical Management ◽

Biochemical Recurrence ◽

Oligometastatic Disease ◽

Psma Pet ◽

Pet Ct ◽

Hormone Sensitive

Metastasis-directed therapy (MDT) in oligometastatic prostate cancer has the potential of delaying the start of androgen deprivation therapy (ADT) and disease progression. We aimed to analyze the efficacy of PSMA-PET/CT in detecting oligometastatic disease (OMD), to look for predictive factors of OMD, and to evaluate the impact of PSMA-PET/CT findings on clinical management. We retrospectively analyzed a homogeneous population of 196 hormone-sensitive prostate cancer patients (HSPC), considered potential candidates for MDT, with a PSMA-PET/CT performed at biochemical recurrence (BCR) after radical prostatectomy (RP). Multivariable logistic regression analysis was performed based on several clinico-pathological factors. Changes in clinical management before and after PSMA-PET/CT were analyzed. The OMD detection rate was 44% for a total positivity rate of 60%. PSMA-PET/CT positivity was independently related to PSA (OR (95%CI), p) (1.7 (1.3–2.3), p < 0.0001) and PSAdt (0.4 (0.2–0.8), p = 0.013), and OMD detection was independently related to PSA (1.6 (1.2–2.2), p = 0.001) and no previous salvage therapy (0.3 (0.1–0.9), p = 0.038). A treatment change was observed in 58% of patients, mostly to perform MDT after OMD detection (60% of changes). This study showed that PSMA-PET/CT is an excellent imaging technique to detect OMD early in HSPC patients with BCR after RP, changing therapeutic management mostly into MDT.

Download Full-text